Cancer medicine journal最新文献_第3页

Years of Fight against Pancreatic Cancer by RGB: Lessons to be Learnt. RGB与胰腺癌抗争的岁月:值得吸取的教训。

Cancer medicine journal Pub Date : 2020-12-01 Epub Date: 2020-11-19

Jessy Warner-Cohen, Jyothi Jose, Muhammad Wasif Saif

引用次数: 0

Social Distancing and the Power of Touch. 社交距离和接触的力量。

Cancer medicine journal Pub Date : 2020-12-01 Epub Date: 2020-05-05

Shamsah Lakhani, Muhammad Wasif Saif

引用次数: 0

Retrospective Analysis of Patients with Gynecological Uterine Sarcomas: Leiomyosarcomas and other Histological Subtypes at a Single Institution from 1996 to 2015. 1996 - 2015年同一医院妇科子宫肉瘤患者的回顾性分析:平滑肌肉瘤和其他组织学亚型

Cancer medicine journal Pub Date : 2020-12-01 Epub Date: 2020-12-07

Olger Nano, Maria J Nieto, Muhammad Wasif Saif, Maher Tarabichi

引用次数: 0

Burden of Proof: Evaluating the Efficacy of Tumor Mutational Burden (TMB) in Predicting Response to Immune Checkpoint Inhibitors. 举证责任:评估肿瘤突变负担(TMB)在预测免疫检查点抑制剂反应中的功效。

Cancer medicine journal Pub Date : 2020-12-01 Epub Date: 2020-11-19

James Newman, Nagashree Seetharamu, Muhammad Wasif Saif

引用次数: 0

ERBB2 FISH and Chromosome Microarray Testing of Gastroesophageal Adenocarcinomas at a Single Institution. ERBB2 FISH和染色体微阵列在单个机构检测胃食管腺癌。

Cancer medicine journal Pub Date : 2020-11-07 DOI: 10.46619/CMJ.2020.3.S1-1006

Alexander Yu, S. Luikart, Gengming Huang, Song Han, Jianping Zhao, L. Soong, Jianli Dong

{"title":"ERBB2 FISH and Chromosome Microarray Testing of Gastroesophageal Adenocarcinomas at a Single Institution.","authors":"Alexander Yu, S. Luikart, Gengming Huang, Song Han, Jianping Zhao, L. Soong, Jianli Dong","doi":"10.46619/CMJ.2020.3.S1-1006","DOIUrl":"https://doi.org/10.46619/CMJ.2020.3.S1-1006","url":null,"abstract":"Overexpression/amplification of erb-b2 receptor tyrosine kinase 2 (ERBB2) is a major prognostic factor in gastroesophageal cancers; it is currently the only biomarker established for the selection of targeted therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). Current standard procedure for determining ERBB2 status in such patients is immunohistochemistry (IHC), followed by in situ hybridization (ISH), when IHC result is equivocal. Insufficient knowledge regarding the utilities of chromosomal microarray (CMA) has hindered its use as an adjunct tool in ERBB2 analysis. Here, we performed CMA on 7 formalin-fixed paraffin-embedded (FFPE) GEA specimens previously tested by ERBB2 fluorescence in situ hybridization (FISH) and evaluated the concordance and performance of CMA. CMA identified 4 (57.1%) samples with amplification of ERBB2, compared to 3 (42.9%) by FISH. CMA also detected several additional DNA copy number variants in these samples, which may have prognostic and therapeutic indications. Further case studies and clinical trials may provide evidence for the utility of CMA-based genomic studies in the management of patients with suspected ERBB2-positive gastroesophageal adenocarcinoma.","PeriodicalId":72513,"journal":{"name":"Cancer medicine journal","volume":"28 1","pages":"39-46"},"PeriodicalIF":0.0,"publicationDate":"2020-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88261802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatectomy for Breast Cancer Metastasis and Sarcoma are more likely to have Adverse Outcomes than Hepatectomy for Primary Hepatocellular Cancer or for Colorectal Metastasis. 乳腺癌转移和肉瘤的肝切除术比原发性肝细胞癌或结直肠转移的肝切除术更有可能产生不良后果。

Cancer medicine journal Pub Date : 2020-11-01 Epub Date: 2020-07-23

Hassan Aziz, Kamil Hanna, Muhammad Wasif Saif, Muhammad Ameen Rauf, Yuri Genyk, Mohd Raashid Sheikh

{"title":"Hepatectomy for Breast Cancer Metastasis and Sarcoma are more likely to have Adverse Outcomes than Hepatectomy for Primary Hepatocellular Cancer or for Colorectal Metastasis.","authors":"Hassan Aziz, Kamil Hanna, Muhammad Wasif Saif, Muhammad Ameen Rauf, Yuri Genyk, Mohd Raashid Sheikh","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: Outcomes for hepatectomy for breast cancer metastasis and sarcomatous disease processes are not well defined in literature. We sought to use a national database to identify outcomes in these patients compared to subset of patients more well studied in literature - primary Hepatocellular cancer patients and patients with colorectal metastasis.Methods: We identified patients undergoing major hepatectomy (≥ 3 segments) for primary hepatocellular cancer (HCC), sarcoma metastasis, breast cancer metastasis, and colorectal metastasis using NSQIP database. The Primary outcome measure was 30-day mortality. Secondary outcome measures were 30-day readmission and complication rates.Results: A total of 5580 patients underwent major hepatectomy during the study period. Patients who underwent hepatectomy for breast cancer metastasis had higher incidence of in-hospital complications (37%) compared to sarcoma (29%), colon (26%), and HCC patients (24%) and 30-days readmission rate (37% vs. 29% - sarcoma vs. 26% - colon vs. 25% HCC). There was no difference in 30-days mortality among the groups.Conclusion: Patients undergoing major hepatectomies for breast cancer metastasis and sarcoma are more likely to have adverse outcomes than compared to their counterparts. This difference highlights the lack of experience in managing breast cancer and sarcoma with metastatic disease to the liver. This also highlights the difference in tumor biology among all the lesions we studied. An extensive discussion should take place when dealing with breast and sarcoma lesions in the liver because of these outcomes.","PeriodicalId":72513,"journal":{"name":"Cancer medicine journal","volume":"3 Suppl 1","pages":"6-12"},"PeriodicalIF":0.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664114/pdf/nihms-1623019.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38607728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gastrointestinal Stromal Tumors Incidentalomas: A Case Series. 胃肠道间质肿瘤偶发瘤:一个病例系列。

Cancer medicine journal Pub Date : 2020-11-01 Epub Date: 2020-10-07

Mina Ferig, Sylvia Alarcon Velasco, Layla Van Doren, Muhammad Wasif Saif

{"title":"Gastrointestinal Stromal Tumors Incidentalomas: A Case Series.","authors":"Mina Ferig, Sylvia Alarcon Velasco, Layla Van Doren, Muhammad Wasif Saif","doi":"","DOIUrl":"","url":null,"abstract":"Background: Gastrointestinal stromal tumors (GISTs) represent approximately 0.2% of all gastrointestinal tumors. GISTs can occur anywhere along the length of the gastrointestinal tract. Most common clinical manifestations of GISTs include GI bleeding, abdominal discomfort, distention and pain. Small lesions can be found incidentally during imaging studies, endoscopy, surgery and post-mortem. The progression of disease from incidentally found indolent to symptomatic disease is unknown.Case series: Here we describe a series of cases of incidentally found GIST and their management. The first patient was a 38-years old morbid obese female with an incidentally found GIST in the stomach following an elective laparoscopic vertical sleeve gastrectomy. The second patient was a 69-year-old male who underwent elective sleeve gastrectomy for his obesity and associated refractory acid reflux. On pathologic examination of the gastrectomy specimen, GIST was diagnosed in the gastric fundus.Discussion: Coexistence of GIST with other malignancies is higher than previously reported and should draw attention of clinicians towards these incidental findings. Prognosis in these patients is usually determined by other malignancy and not significantly influenced by GIST. Therefore, treatment algorithms should be focused on prognostically relevant malignancy.","PeriodicalId":72513,"journal":{"name":"Cancer medicine journal","volume":"3 Suppl 1","pages":"35-38"},"PeriodicalIF":0.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664112/pdf/nihms-1641599.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38607729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gastrointestinal Stromal Tumors Incidentalomas: A Case Series. 胃肠道间质肿瘤偶发瘤:一个病例系列。

Cancer medicine journal Pub Date : 2020-10-07 DOI: 10.46619/CMJ.2020.3.S1-1005

Mina Ferig, S. A. Alarcon Velasco, Layla Van Doren, M. Saif

{"title":"Gastrointestinal Stromal Tumors Incidentalomas: A Case Series.","authors":"Mina Ferig, S. A. Alarcon Velasco, Layla Van Doren, M. Saif","doi":"10.46619/CMJ.2020.3.S1-1005","DOIUrl":"https://doi.org/10.46619/CMJ.2020.3.S1-1005","url":null,"abstract":"BACKGROUND\u0000Gastrointestinal stromal tumors (GISTs) represent approximately 0.2% of all gastrointestinal tumors. GISTs can occur anywhere along the length of the gastrointestinal tract. Most common clinical manifestations of GISTs include GI bleeding, abdominal discomfort, distention and pain. Small lesions can be found incidentally during imaging studies, endoscopy, surgery and post-mortem. The progression of disease from incidentally found indolent to symptomatic disease is unknown.\u0000\u0000\u0000CASE SERIES\u0000Here we describe a series of cases of incidentally found GIST and their management. The first patient was a 38-years old morbid obese female with an incidentally found GIST in the stomach following an elective laparoscopic vertical sleeve gastrectomy. The second patient was a 69-year-old male who underwent elective sleeve gastrectomy for his obesity and associated refractory acid reflux. On pathologic examination of the gastrectomy specimen, GIST was diagnosed in the gastric fundus.\u0000\u0000\u0000DISCUSSION\u0000Coexistence of GIST with other malignancies is higher than previously reported and should draw attention of clinicians towards these incidental findings. Prognosis in these patients is usually determined by other malignancy and not significantly influenced by GIST. Therefore, treatment algorithms should be focused on prognostically relevant malignancy.","PeriodicalId":72513,"journal":{"name":"Cancer medicine journal","volume":"83 1","pages":"35-38"},"PeriodicalIF":0.0,"publicationDate":"2020-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87379246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Hepatectomy for Breast Cancer Metastasis and Sarcoma are more likely to have Adverse Outcomes than Hepatectomy for Primary Hepatocellular Cancer or for Colorectal Metastasis. 乳腺癌转移和肉瘤的肝切除术比原发性肝细胞癌或结直肠转移的肝切除术更有可能产生不良后果。

Cancer medicine journal Pub Date : 2020-07-23 DOI: 10.46619/CMJ.2020.3.S1-1002

H. Aziz, K. Hanna, M. Saif, M. A. Rauf, Y. Genyk, M. Sheikh

{"title":"Hepatectomy for Breast Cancer Metastasis and Sarcoma are more likely to have Adverse Outcomes than Hepatectomy for Primary Hepatocellular Cancer or for Colorectal Metastasis.","authors":"H. Aziz, K. Hanna, M. Saif, M. A. Rauf, Y. Genyk, M. Sheikh","doi":"10.46619/CMJ.2020.3.S1-1002","DOIUrl":"https://doi.org/10.46619/CMJ.2020.3.S1-1002","url":null,"abstract":"INTRODUCTION\u0000Outcomes for hepatectomy for breast cancer metastasis and sarcomatous disease processes are not well defined in literature. We sought to use a national database to identify outcomes in these patients compared to subset of patients more well studied in literature - primary Hepatocellular cancer patients and patients with colorectal metastasis.\u0000\u0000\u0000METHODS\u0000We identified patients undergoing major hepatectomy (≥ 3 segments) for primary hepatocellular cancer (HCC), sarcoma metastasis, breast cancer metastasis, and colorectal metastasis using NSQIP database. The Primary outcome measure was 30-day mortality. Secondary outcome measures were 30-day readmission and complication rates.\u0000\u0000\u0000RESULTS\u0000A total of 5580 patients underwent major hepatectomy during the study period. Patients who underwent hepatectomy for breast cancer metastasis had higher incidence of in-hospital complications (37%) compared to sarcoma (29%), colon (26%), and HCC patients (24%) and 30-days readmission rate (37% vs. 29% - sarcoma vs. 26% - colon vs. 25% HCC). There was no difference in 30-days mortality among the groups.\u0000\u0000\u0000CONCLUSION\u0000Patients undergoing major hepatectomies for breast cancer metastasis and sarcoma are more likely to have adverse outcomes than compared to their counterparts. This difference highlights the lack of experience in managing breast cancer and sarcoma with metastatic disease to the liver. This also highlights the difference in tumor biology among all the lesions we studied. An extensive discussion should take place when dealing with breast and sarcoma lesions in the liver because of these outcomes.","PeriodicalId":72513,"journal":{"name":"Cancer medicine journal","volume":"41 1","pages":"6-12"},"PeriodicalIF":0.0,"publicationDate":"2020-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77293633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Cancer on Twitter. 推特上的癌症

Cancer medicine journal Pub Date : 2020-05-12 DOI: 10.46619/CMJ.2020.3-1025

M. Saif

引用次数: 0